Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy-Reference-Cited by-同舟云学术

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy

Published:2023-07-24 Issue:8 Volume:23 Page:817-833
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Leal Ticiana¹,Socinski Mark A²

Affiliation:

1. Emory University Winship Cancer Institute, USA

2. AdventHealth Cancer Institute, Orlando, Florida, USA

Funder

Publication Practice Counsel™; Truposha LLC

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2235895

Reference136 articles.

1. National Cancer Institute. SEER. Cancer stat facts: lung and bronchus cancer [cited Jun 3, 2022]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. The Effect of Advances in Lung-Cancer Treatment on Population Mortality

4. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer

5. Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial;The Lancet Respiratory Medicine;2024-09

2. Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade;Journal of Clinical Oncology;2024-07-10